Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 1:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,118 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: RHEUMATOID ARTHRITIS Clear all
Completed No phase listed Observational Accepts healthy volunteers

Low Density Lipoprotein Cholesterol (CLDL) as a Cardiovascular Disease Risk Factor in Rheumatoid Arthritis

NCT01105715
View directory record Official record
Conditions
Rheumatoid Arthritis, Cardiovascular Disease
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 21, 2026, 1:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

KickStart30: A 30-Day Intervention for Patients With Rheumatoid Arthritis (RA)

NCT03993548
View directory record Official record
Conditions
Chronic Pain, Stress, Psychological, Healthy, Rheumatoid Arthritis
Interventions
Wellness Element 1 - Exercise, Wellness Element 2 - Mindfulness, Wellness Element 3 - Sleep Hygiene, Wellness Element 4 - Social Connectedness, Wellness Element 5 - Nutrition, Wellness Element 6 - Wellness Exercises, Wellness Element 7 - Motivational Messages
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Sep 21, 2026, 1:58 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study Evaluating the Safety and Efficacy of Cura-100 in Subjects With Rheumatoid Arthritis and Osteoarthritis

NCT00455208
View directory record Official record
Conditions
Rheumatoid Arthritis, Osteoarthritis
Interventions
Cura-100
Drug
Lead sponsor
Cura Biotech LLC
Industry
Eligibility
20 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2009 · Synced Sep 21, 2026, 1:58 PM EDT
Enrolling by invitation No phase listed Observational

CorEvitas Rheumatoid Arthritis (RA) Drug Safety & Effectiveness Registry

NCT01402661
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
CorEvitas
Network
Eligibility
18 Years and older
Enrollment
91,758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2100
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 21, 2026, 1:58 PM EDT
Terminated Phase 3 Interventional Results available

A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate

NCT01198002
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LY2127399, Placebo Q2W, Placebo Q4W, Methotrexate
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,041 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
75
States / cities
Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Sep 21, 2026, 1:58 PM EDT
Completed Early Phase 1 Interventional

Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases

NCT02925351
View directory record Official record
Conditions
Autoimmune Disease, Crohn Disease, Inflammatory Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Takayasu Arteritis
Interventions
Computed Tomography, Fluorine F 18 Clofarabine, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Sep 21, 2026, 1:58 PM EDT
Completed Phase 2 Interventional

A Study Using Intravenous Paxceed™ to Treat Patients With Rheumatoid Arthritis

NCT00055133
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Micellar Paclitaxel for Injection
Drug
Lead sponsor
Angiotech Pharmaceuticals
Industry
Eligibility
21 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
9
States / cities
Birmingham, Alabama • Denver, Colorado • Daytona Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2008 · Synced Sep 21, 2026, 1:58 PM EDT
Recruiting Phase 1 Interventional

A Study of AZD0120 in Autoimmune Diseases

NCT07295847
View directory record Official record
Conditions
Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
Interventions
AZD0120
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Tucson, Arizona • Stanford, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 21, 2026, 1:58 PM EDT
Completed Phase 3 Interventional Results available

A Study in Moderate to Severe Rheumatoid Arthritis

NCT01710358
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab, Baricitinib, Methotrexate, Adalimumab Placebo, Baricitinib Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
45
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Sep 21, 2026, 1:58 PM EDT
Completed Phase 2 Interventional

A Multicentre Trial to Determine the Efficacy of AD 452 in RA Subjects.

NCT00141934
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AD 452
Drug
Lead sponsor
Sosei
Industry
Eligibility
18 Years to 75 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
10
States / cities
Clearwater, Florida • Fort Lauderdale, Florida • Ocala, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2007 · Synced Sep 21, 2026, 1:58 PM EDT
Completed Phase 1 Interventional Results available

Co-Administration Of Methotrexate And CP-690,550

NCT01745055
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550 (tofacitinib), Methotrexate (MTX)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
4
States / cities
Daytona Beach, Florida • Fort Lauderdale, Florida • Miramar, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 21, 2026, 1:58 PM EDT
Completed Not applicable Interventional Results available

Dietary Salt in Rheumatoid Arthritis

NCT03649178
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
salt
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 21, 2026, 1:58 PM EDT
Active, not recruiting Not applicable Interventional

Insignia™ Hip Stem Outcomes Study

NCT05144191
View directory record Official record
Conditions
Hip Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis, Post-traumatic Osteoarthritis, Femoral Neck Fractures, Trochanteric Fractures, Surgery
Interventions
Insignia uncemented Hip Stem
Device
Lead sponsor
Stryker Orthopaedics
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2034
U.S. locations
11
States / cities
Phoenix, Arizona • San Francisco, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 21, 2026, 1:58 PM EDT
Completed No phase listed Observational

Assessment of Macrophage Activation syndromE in STill's Disease

NCT06405152
View directory record Official record
Conditions
Macrophage Activation Syndrome, Still's Disease, Adult-Onset, Stills Disease, Juvenile-Onset
Interventions
Chart review
Other
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
6 Months to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Atlanta, Georgia • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Sep 21, 2026, 1:58 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab

NCT00808210
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Infliximab, Methotrexate, Methylprednisolone, Ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
53
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Murrieta, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Sep 21, 2026, 1:58 PM EDT
Terminated No phase listed Observational

Efficacy of the CLP® Hip - Retrospective

NCT00764842
View directory record Official record
Conditions
Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis
Interventions
Encore CLP® Hip stem
Device
Lead sponsor
Encore Medical, L.P.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2011 · Synced Sep 21, 2026, 1:58 PM EDT
Completed No phase listed Observational

Corneal Nerve Structure in Sjogren's

NCT03203382
View directory record Official record
Conditions
Sjogren's Syndrome, Vitamin D Deficiency
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Sep 21, 2026, 1:58 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)

NCT02706951
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, Upadacitinib, Placebo Upadacitinib, Placebo Methotrexate
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
52
States / cities
Huntsville, Alabama • Mobile, Alabama • Gilbert, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 21, 2026, 1:58 PM EDT
Terminated Phase 3 Interventional Results available

An Open Label Study for Participants With Rheumatoid Arthritis

NCT01215942
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LY2127399
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,086 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
127
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2018 · Synced Sep 21, 2026, 1:58 PM EDT
Terminated Phase 2 Interventional

A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

NCT01679951
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, JNJ-38518168 (3 mg), JNJ-38518168 (10 mg), JNJ-38518168 (30 mg), Methotrexate
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Huntsville, Alabama • Gilbert, Arizona • Covina, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2019 · Synced Sep 21, 2026, 1:58 PM EDT
Completed Not applicable Interventional

Gold Factor on Knee Joint Health and Function

NCT05347602
View directory record Official record
Conditions
Knee Arthritis, Knee Osteoarthritis, Knee Pain Chronic, Knee Discomfort, Rheumatoid Arthritis, Knee Pain Swelling
Interventions
Gold Factor (Gold Nanoparticles, AuNPs), Placebo
Dietary Supplement
Lead sponsor
4Life Research, LLC
Industry
Eligibility
18 Years to 87 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Sep 21, 2026, 1:58 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)

NCT03970837
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Tofacitinib, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
64
States / cities
Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 21, 2026, 1:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Research Protocol for Karuna Labs Inc.: Safety and Efficacy of Virtual Reality Graded Motor Imagery for Chronic Pain

NCT04060875
View directory record Official record
Conditions
Chronic Pain, Low Back Pain, Fibromyalgia, Upper Extremity Dysfunction, Complex Regional Pain Syndromes, Phantom Limb Pain, Rheumatoid Arthritis, Carpal Tunnel Syndrome, Repetitive Strain Injury
Interventions
Karuna Labs Virtual Reality Software
Device
Lead sponsor
Karuna Labs Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 21, 2026, 1:58 PM EDT
Completed Not applicable Interventional

The CORRONA Treat to Target Trial: Outcomes and Feasibility in a US Population

NCT01407419
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Treatment Acceleration, Monthly Assessment
Other
Lead sponsor
CorEvitas
Network
Eligibility
18 Years and older
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Sep 21, 2026, 1:58 PM EDT